Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trodusquemine - NeuBase Therapeutics

Next Previous
X
Search
Drug Profile

Trodusquemine - NeuBase Therapeutics

Alternative Names: MSI-1436; MSI-1436C; Produlestan; Trodulamine

Latest Information Update: 28 Jun 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genaera Corporation
  • Developer DepYmed; Genaera Corporation
  • Class Anorectics; Antihyperglycaemics; Antineoplastics; Antivirals; Biogenic amines; Cholestanes; Obesity therapies; Polyamines; Sulfates
  • Mechanism of Action Adrenergic uptake inhibitors; Apoptosis stimulants; Dopamine uptake inhibitors; Neuropeptide Y modulators; Protein tyrosine phosphatase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported HER2 positive breast cancer
  • Discontinued Diabetes mellitus; HIV infections; Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 28 Jun 2022 No recent reports of development identified for phase-I development in Breast-cancer(Metastatic disease, Second-line therapy or greater) in USA (IV)
  • 28 Jan 2020 Trodusquemine is still in phase I trials for HER2-positive breast cancer in USA (DepYmed pipeline, January 2020)
  • 28 Jan 2020 Trodusquemine is available for licensing as of 28 Jan 2020. https://depymedinc.com (DepYmed pipeline, January 2020)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top